Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Ischemic Stroke
Interventions: Normal saline; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 110 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Knee Osteoarthritis
Interventions: Platelet Rich Plasma, Normal Saline; Biological · Other
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 40 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: University of Oxford; Other
Eligibility: 40 Years and older
Enrollment: 16,124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2049
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pain, Postoperative, Satisfaction
Interventions: Ropivacaine, Normal saline; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Ventricular Tachycardia, Ventricular Arrhythmias, Ventricular Fibrillation, Recurrent Ventricular Tachycardia
Interventions: Dexmedetomidine, Normal saline; Drug
Lead sponsor: Ottawa Heart Institute Research Corporation; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Heterozygous Familial Hypercholesterolemia, Elevated Cholesterol
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 10
States / cities: Mission Viejo, California • Newport Beach, California • Stanford, California + 7 more

Conditions: Moderate-to-severely Painful Ankle Surgery
Interventions: Popliteal nerve block including liposomal bupivacaine, Adductor canal nerve block including liposomal bupivacaine, Continuous popliteal nerve block with normal saline, Popliteal nerve block with exclusively unencapsulated bupivacaine, Adductor canal nerve block with exclusively unencapsulated bupivacaine, Continuous popliteal nerve block with unencapsulated bupivacaine; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Chronic Pain, Depression
Interventions: Ketamine, Normal saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Septic Shock
Interventions: FE 202158 1.25, FE 202158 2.5, FE 202158 3.75, Placebo; Drug · Other
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 6
States / cities: Newark, Delaware • Springfield, Massachusetts • Duluth, Minnesota + 3 more

Conditions: COVID-19, SARS-CoV-2
Interventions: VYD222 (pemivibart), Normal saline; Drug
Lead sponsor: Invivyd, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 790 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 18
States / cities: Fullerton, California • Long Beach, California • Rolling Hills Estates, California + 15 more

Conditions: End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
Interventions: C1 Esterase Inhibitor, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pulmonary Sarcoidosis
Interventions: PD 0360324, Normal Saline for injection; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 5
States / cities: New York, New York • Cincinnati, Ohio

Conditions: Erectile Dysfunction
Interventions: Autologous Platelet Rich Plasma, Saline solution; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 30 Years to 75 Years · Male only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute Kidney Injury, Mechanical Ventilation
Interventions: Amino Acid infusion, Lactated ringers solution; Drug
Lead sponsor: Dana Fuhrman; Other
Eligibility: Up to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Surgery, Infection
Interventions: Polymyxin B in Normal Saline, Placebo: Normal Saline; Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 88 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Salt Sensitivity of Blood Pressure
Interventions: Hypertonic Saline with furosemide, Hypertonic Saline without furosemide; Other
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 45 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Induction of Labor Affected Fetus / Newborn
Interventions: Lactated ringers, 5% dextrose lactated ringers; Other
Lead sponsor: Ascension Health; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Grand Blanc, Michigan

Conditions: Overactive Bladder
Interventions: botulinum toxin Type A (200U), botulinum toxin Type A (300U), Normal Saline (Placebo); botulinum toxin Type A (200U), Normal Saline (Placebo); botulinum toxin Type A (300U); Biological · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Application Site Discomfort, Medical Device Discomfort
Interventions: Bupivacaine with Epinephrine, Normal Saline; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Respiratory Infection, Bacterial Resistance, Respiratory Failure
Interventions: vancomycin or gentamicin, Placebo; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Postoperative Pain
Interventions: Extended-Release liposomal bupivacaine (Exparel), Normal saline; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Local Anesthetics
Interventions: Lidocaine, normal saline, alkalinized lidocaine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 19 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Migraine, Headache, Episodic Migraine
Interventions: Lidocaine 4% Topical Application Cream [LMX 4], Lidocaine Hydrochloride 2 mg/mL Injectable Solution, Normal Saline; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 7 Years to 21 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lupus Nephritis
Interventions: Daxdilimab, Placebo (Normal Saline); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Birmingham, Alabama • San Dimas, California • Syracuse, New York + 2 more

Search by objective public record fields.

Bolus of Saline in Stroke

Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical & Imaging Outcome Correlation

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

Superficial Cervical Plexus Blockade for Clavicle Fracture Analgesia

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

Liposomal Bupivacaine Versus Continuous Peripheral Nerve Blocks for Analgesia Following Ankle Surgery

Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression

Effects of the V1a Agonist FE 202158 in Patients With Septic Shock

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis

Safety and Efficacy of Autologous Platelet-Rich Plasma for Erectile Dysfunction.

Biomarker and Renal Angina Validation to Assess Heart-Kidney Outcomes After Amino Acid Therapy

Antibiotic Irrigation for Pancreatoduodenectomy

Central Sodium Sensing: Implications for Blood Pressure Regulation

The Use of D5LR Versus LR for Induction of Labor and Time to Delivery in Multiparous and Primiparous Patient's With Favorable and Unfavorable Bishop's Scores

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Control of Tourniquet Pain With an Axillary Ring of Subcutaneous Local Anesthetic

Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit

Efficacy of Extended-Release Liposomal Bupivacaine for Post-Operative Urogynecologic Surgery

Clinical Study to Evaluate the Effect of pH on Pain Upon Local Anesthetic Administration.

Occipital Blocks for Acute Migraine

Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)